Metabolic and clinical effects of progestogens

@article{Wiegratz2006MetabolicAC,
  title={Metabolic and clinical effects of progestogens},
  author={Inka Wiegratz and Herbert Kuhl},
  journal={The European Journal of Contraception \& Reproductive Health Care},
  year={2006},
  volume={11},
  pages={153 - 161}
}
  • I. Wiegratz, H. Kuhl
  • Published 1 January 2006
  • Medicine
  • The European Journal of Contraception & Reproductive Health Care
Synthetic progestogens differ not only in their hormonal potency, but also in their spectrum of hormonal activities. Beside their progestogenic and anti-oestrogenic effects, they may exert oestrogenic, androgenic, antiandrogenic, glucocorticoid and/or anti-mineralocorticoid activities. Consequently, progestogens may influence various metabolic parameters and modulate oestrogen-induced alterations in lipid metabolism, haemostasis, and various other factors. Progestogens with androgenic… 
Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis
ABSTRACT Introduction: The pharmacodynamic effects of various combined oral estrogen-progestin combinations (COC) are examined for their components alone or in the various combined formulations.
Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective, randomised study
  • S. Palacios, E. Colli, P. Regidor
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2021
TLDR
The results confirm the beneficial properties of the drospirenone-only pill on a variety of metabolic parameters and on coagulatory parameters, and there was no impact on hemostasis.
Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference
TLDR
Micronized progesterone and dydrogesterone appear to be the safest options, with lower associated cardiovascular, thromboembolic, and breast cancer risks compared with other progestogens, and are the first-choice options for use in ‘special situations,’ such as in women with high-density breast tissue, diabetes, obesity, smoking, and risk factors for venous throm boembolism.
Hormonal Contraceptives and the Risk of Venous Thrombosis.
TLDR
It is hypothesized that switching COCs, even when switching from a high- to a low-risk COC, increases the risk of venous thrombosis, and it is important to identify women at risk of VT and advise them on alternative contraception methods.
Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol
TLDR
Administration of E2V/DNG does not influence lipid and glucose metabolism, while mixed effect are exerted by EE/CMA, both preparations reduce bone metabolism without influencing short-term effect on body composition.
Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk
TLDR
This review discusses the numerous strategies that have been implemented to reduce the thrombotic risk associated with combined oral contraceptives (COCs) from their arrival on the market until today and considers the endogenous thrombin potential-based APC resistance assay.
Progestin potency – Assessment and relevance to choice of oral contraceptives
TLDR
Newer progestin potency are more receptor selective and potency is less relevant than it was with older progestins, and the use of the EPA can help eliminate this.
The effects of hormonal contraceptives on bone turnover markers and bone health
TLDR
The effects of combined and gestagen‐only hormonal contraceptives on bone turnover markers and related effects on bone mineral density and fracture risk in premenopausal women, as documented in the literature until January 2009 are reviewed.
Micronized progesterone, progestins, and menopause hormone therapy
TLDR
A narrative review on the balance between benefit/risk using P versus PGs in menopause hormone therapy (MHT) is conducted to aid clinician to choose the best regimens, specifically the PG component of hormone therapy, for women with bothersome menopausal symptoms and with a uterus.
Effects of different progestins on prostaglandin biosynthesis in human endometrial explants.
TLDR
Among the tested progestins, CMA displayed the most consistent suppression of prostaglandin biosynthesis in human endometrial explants, which supports clinical observations about the efficacy of chlormadinone acetate in dysmenorrhea treatment.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
Clinical profile of contraceptive progestins
  • G. Benagiano, F. Primiero, M. Farris
  • Medicine
    The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2004
TLDR
It has been amply proven that - even when administered in doses that do not constantly inhibit ovulation - a progestin can still remain effective as a contraceptive by acting at the level of the cervical mucus and, at least in part, of the endometrium.
Pharmacology of estrogens and progestogens: influence of different routes of administration
  • H. Kuhl
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2005
This review comprises the pharmacokinetics and pharmacodynamics of natural and synthetic estrogens and progestogens used in contraception and therapy, with special consideration of hormone
Sex Steroids Used in Hormonal Treatment Increase Vascular Procoagulant Activity by Inducing Thrombin Receptor (PAR-1) Expression: Role of the Glucocorticoid Receptor
TLDR
It is demonstrated that several progestins markedly potentiate the vascular procoagulant effects of thrombin by increasing the availability of membraneThrombin receptors in the smooth muscle, an effect that is most likely due to their glucocorticoid-like activity.
Managing cutaneous manifestations of hyperandrogenic disorders: the role of oral contraceptives.
TLDR
OCs with a predominant estrogen effect may improve mild to moderate forms of acne and seborrhea, hirsutism and androgenetic alopecia, in a time-dependent manner, according to type and dose.
Changes of hemostatic variables during oral contraceptive use.
TLDR
Recent evidence indicates that the prothrombotic effect of the estrogen component ethinylestradiol in combined OC is counteracted by the progestagen component present in these preparations and that third-generation progestagens such as desogestrel or gestodene are less efficient with respect to this than the second- generation progESTagen levonorgestrel.
Effect of four oral contraceptives on hemostatic parameters.
TLDR
The results show an antagonistic effect of LNG on the EE-induced rise of factor VII activity and fragment 1+2 and on theEE-dependent reduction of total and free protein S.
...
1
2
3
...